Prudential Financial Inc. lessened its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 57.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 88,121 shares of the life sciences company's stock after selling 120,100 shares during the quarter. Prudential Financial Inc. owned approximately 0.11% of Integra LifeSciences worth $1,999,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently modified their holdings of the company. Principal Financial Group Inc. lifted its position in Integra LifeSciences by 18.7% during the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company's stock valued at $7,294,000 after purchasing an additional 63,266 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Integra LifeSciences by 824.5% in the third quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company's stock worth $2,031,000 after buying an additional 99,685 shares during the period. Systematic Financial Management LP lifted its position in shares of Integra LifeSciences by 53.9% during the 3rd quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company's stock valued at $11,115,000 after buying an additional 214,272 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Integra LifeSciences by 15.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company's stock worth $17,158,000 after acquiring an additional 125,620 shares in the last quarter. Finally, MetLife Investment Management LLC raised its stake in Integra LifeSciences by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 39,638 shares of the life sciences company's stock worth $720,000 after acquiring an additional 22,334 shares during the period. Institutional investors own 84.78% of the company's stock.
Integra LifeSciences Price Performance
Shares of IART stock traded up $0.01 during mid-day trading on Monday, hitting $19.58. The company had a trading volume of 768,282 shares, compared to its average volume of 1,045,522. The company has a market capitalization of $1.51 billion, a P/E ratio of -217.53, a P/E/G ratio of 0.73 and a beta of 1.24. The stock's 50 day moving average price is $23.37 and its 200-day moving average price is $22.34. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $34.79. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. The business's revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.89 EPS. Equities research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.
Analyst Ratings Changes
Separately, Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $23.00.
Check Out Our Latest Stock Analysis on IART
Integra LifeSciences Company Profile
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Stories
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
